BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,960,977 | -18.4% | 43,499 | -2.2% | 0.02% | -13.6% |
| Q2 2023 | $3,630,821 | +12.3% | 44,479 | +2.0% | 0.02% | +4.8% |
| Q1 2023 | $3,233,794 | -10.1% | 43,588 | +0.4% | 0.02% | -16.0% |
| Q4 2022 | $3,596,578 | +12.0% | 43,395 | +283.8% | 0.02% | +8.7% |
| Q3 2022 | $3,211,000 | -20.0% | 11,306 | -2.3% | 0.02% | -14.8% |
| Q2 2022 | $4,012,000 | -22.9% | 11,575 | -3.7% | 0.03% | -6.9% |
| Q1 2022 | $5,205,000 | -18.4% | 12,020 | -2.5% | 0.03% | -9.4% |
| Q4 2021 | $6,375,000 | +8.0% | 12,322 | +1.2% | 0.03% | +3.2% |
| Q3 2021 | $5,901,000 | -81.1% | 12,178 | -82.5% | 0.03% | -70.8% |
| Q2 2021 | $31,258,000 | +15.8% | 69,422 | -1.8% | 0.11% | +11.6% |
| Q1 2021 | $26,997,000 | +21.3% | 70,687 | +0.8% | 0.10% | +15.9% |
| Q4 2020 | $22,258,000 | +26.3% | 70,093 | -1.4% | 0.08% | -2.4% |
| Q3 2020 | $17,619,000 | -7.2% | 71,121 | -1.1% | 0.08% | -8.7% |
| Q2 2020 | $18,993,000 | +34.3% | 71,923 | -3.5% | 0.09% | +19.5% |
| Q1 2020 | $14,139,000 | -12.8% | 74,565 | +1.0% | 0.08% | +22.2% |
| Q4 2019 | $16,208,000 | +13.0% | 73,835 | +0.7% | 0.06% | +8.6% |
| Q3 2019 | $14,346,000 | -7.4% | 73,319 | -1.3% | 0.06% | -4.9% |
| Q2 2019 | $15,490,000 | +3.3% | 74,297 | -1.6% | 0.06% | +7.0% |
| Q1 2019 | $14,997,000 | +34.2% | 75,534 | -2.1% | 0.06% | +23.9% |
| Q4 2018 | $11,171,000 | -28.8% | 77,192 | +0.4% | 0.05% | -11.5% |
| Q3 2018 | $15,699,000 | +39.9% | 76,914 | +1.4% | 0.05% | +33.3% |
| Q2 2018 | $11,218,000 | -1.0% | 75,822 | +1.1% | 0.04% | -2.5% |
| Q1 2018 | $11,332,000 | +12.7% | 75,028 | -3.3% | 0.04% | +21.2% |
| Q4 2017 | $10,053,000 | +8.9% | 77,603 | +1.6% | 0.03% | 0.0% |
| Q3 2017 | $9,233,000 | +2.8% | 76,375 | -0.1% | 0.03% | +3.1% |
| Q2 2017 | $8,980,000 | +18.7% | 76,426 | +2.7% | 0.03% | +14.3% |
| Q1 2017 | $7,567,000 | +2.5% | 74,439 | +3.7% | 0.03% | 0.0% |
| Q4 2016 | $7,380,000 | -99.9% | 71,767 | -0.0% | 0.03% | -9.7% |
| Q3 2016 | $7,860,786,000 | -2.9% | 71,788 | +0.0% | 0.03% | -8.8% |
| Q2 2016 | $8,092,150,000 | +19.1% | 71,758 | -0.2% | 0.03% | +25.9% |
| Q1 2016 | $6,795,000,000 | +5.0% | 71,888 | -0.0% | 0.03% | 0.0% |
| Q4 2015 | $6,471,000,000 | +94588.3% | 71,899 | -2.7% | 0.03% | -10.0% |
| Q3 2015 | $6,834,000 | -99.9% | 73,912 | -0.0% | 0.03% | +3.4% |
| Q2 2015 | $7,280,774,000 | -1.8% | 73,939 | -0.0% | 0.03% | -6.5% |
| Q1 2015 | $7,415,542,000 | +11.1% | 73,941 | +2.3% | 0.03% | +6.9% |
| Q4 2014 | $6,676,085,000 | – | 72,252 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |